Protection against Covid-19 by BNT162b2 Booster across Age Groups
Abstract BACKGROUND After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons 60 years of age or older, th…
